Remedium Bio has secured $10 million in Series A funding to develop adjustable gene therapies that reprogram fat cells to produce therapeutic proteins long-term. The platform's ability to modulate protein expression after treatment addresses a fundamental limitation of traditional gene therapy: the inability to change dosing once administered.
Key Points
- Adipocytes engineered to manufacture therapeutic proteins for years
- Expression levels remain adjustable after initial treatment administration
- Localized subcutaneous injection reduces systemic vector exposure and toxicity
Longevity Analysis
This approach transforms chronic disease management by shifting from repeated exogenous dosing to endogenous production within the body's own cells. The critical advance is dose control after treatment—addressing a core vulnerability of irreversible gene therapies where biology changes, therapeutic needs shift, or initial dosing proves suboptimal. For conditions requiring sustained protein replacement, the combination of durability with adjustability reduces the binary choice between therapeutic permanence and therapeutic impotence, enabling precision calibration as the patient's physiology evolves.
Original published by Longevity.Technology, by Eleanor Garth.